||(-)-Verbenone (2-Pinen-4-one), an important component of the essential oil from rosemary, is an insect pheromone with a spicy odor and camphoraceous fragrance.
||1V209 (TLR7 agonist T7)
||1V209 (T7, TLR7 agonist T7) is an agonist of Toll-like receptor 7 (TLR7) with anti-tumor effects. 1V209 can be used as vaccine adjuvants, enhances antigen specific humoral and cellular immune responses.
||4-Vinylcyclohexene dioxide (Vinylcyclohexene dioxide, VCD) is a chemical used to induce menopause and decrease estrogen production. 4-Vinylcyclohexene dioxide is used as a crosslinking agent for the production of epoxy resins.
||V-9302 is a competitive small molecule antagonist of transmembrane glutamine flux, that selectively and potently targets the amino acid transporter ASCT2 (SLC1A5) with an IC50 value of 9.6 μM for inhibition of glutamine uptake in HEK-293 cells. V-9302 blocks Sodium-neutral AA transporter 2 (SNAT2, SLC38A2) and the large neutral AA transporter 1 (LAT1, SLC7A5) as observed in 143B osteosarcoma cells, HCC1806 breast cancer cells and Xenopus laevis oocytes.
||Vactosertib (TEW-7197, EW-7197) is a highly potent, selective, and orally bioavailable TGF-β receptor ALK4/ALK5 inhibitor with IC50 of 13 nM and 11 nM, respectively. Phase 1.
||Vacuolin-1 is a potent and cell-permeable inhibitor that blocks the Ca(2+)-dependent exocytosis of lysosomes and prevents the release of lysosomal content without affecting the process of resealing. Vacuolin-1 is also a potent and selective PIKfyve inhibitor, and inhibits autophagy by impairing lysosomal maturation via PIKfyve inhibition.
||Vadadustat (AKB-6548, B-506, PG-1016548) is a novel, titratable, oral HIF-PH inhibitor.
||Vadimezan (ASA404, NSC 640488, DMXAA) is a vascular disrupting agents (VDA) and competitive inhibitor of DT-diaphorase with Ki of 20 μM and IC50 of 62.5 μM in cell-free assays, respectively. DMXAA (Vadimezan) is also a STING agonist with potential antineoplastic activity. DMXAA (Vadimezan) potently induces IFN-β but relatively low TNF-α expression in vitro. DMXAA (Vadimezan) has antiviral activity. Phase 3.
||Val-cit-PAB-OH is a cleavable linker of antibody-drug-conjugation (ADC).
||Val-Lys(Boc)-PAB, a ADC linker, is used as a non-linear self-immolative linker for reducing hydrophobicity of antibody-drug conjugates (ADCs) for cancer therapy.
||Valaciclovir HCl, an aciclovir prodrug, inhibits activity of virus DNA polymerase, used to treat infections caused by herpes simplex virus (HSV) and varicella zoster virus, and for prophylaxis against cytomegalovirus (CMV).
||Valbenazine tosylate (NBI-98854) is the tosylate salt of valbenazine, a vesicular monoamine transporter 2 (VMAT2) inhibitor with a Ki value of 150 nM while displaying no significant binding to VAMT1(Ki<10 μM).
||Valdecoxib is a potent and selective inhibitor of COX-2 with IC50 of 5 nM.
||Valemetostat (DS-3201, DS-3201b) is a selective EZH1/2 dual inhibitor.
||Valethamate bromide (Ediposin) is an alkylbenzene which is useful for facilitating cervical ripening, dilatation and thereby decreasing the duration of labor.
||Valganciclovir HCl is a prodrug for ganciclovir with antiviral activity used to treat cytomegalovirus infections.
||Valnemulin HCl is a broad-spectrum bacteriostatic agent inhibiting protein synthesis in bacteria by binding to the peptidyl transferase component of the 50S subunit of ribosomes.
||Valproic Acid (NSC 93819) sodium salt
||Valproic Acid sodium salt (NSC 93819, Sodium valproate) is a HDAC inhibitor by selectively inducing proteasomal degradation of HDAC2, used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches. Valproic acid induces Notch1 signaling in small cell lung cancer (SCLC) cells. Valproic acid is under investigation for treatment of HIV and various cancers. Valproic acid (VPA) induces autophagy and mitophagy by upregulation of BNIP3 and mitochondrial biogenesis by upregulating PGC-1α.
||Valproic acid (VPA)
||Valproic acid (VPA, 2-Propylvaleric Acid, Valproate) is a fatty acid with anticonvulsant properties used in the treatment of epilepsy. It is also a histone deacetylase (HDAC) inhibitor and is under investigation for treatment of HIV and various cancers. Valproic acid (VPA) induces autophagy and mitophagy by upregulation of BNIP3 and mitochondrial biogenesis by upregulating PGC-1α. Valproic acid activates Notch-1 signaling.
||Valpromide (Depamide, Dipropylacetamide, 2-propylpentanamide) is an antiepileptic drug, derivative of Valproic acid (VPA), used as a mood-stabilizer in bipolar disorder. Valpromide inhibits both viral and cellular gene expression. Valpromide is a human epoxide hydrolase inhibitor.
||Valrocemide (N-Valproylglycinamide, TV1901) is a promising antiepileptic drug candidate with a broad spectrum of anticonvulsant activity.
||Valrubicin is a chemotherapy drug used to treat bladder cancer. Valrubicin is a chemotherapy agent, inhibits TPA- and PDBu-induced PKC activation with IC50s of 0.85 and 1.25 μM, respectively.
||Valsartan (CGP-48933) is a selective angiotensin II receptor antagonist, used to treat high blood pressure and congestive heart failure.
||Vancomycin is an antibiotic used to treat serious bacterial infections. It works by stopping the growth of bacteria.
||Vancomycin HCl is a hydrochloride of vancomycin that is a narrow-spectrum glycopeptide antibacterial agent.
||Vandetanib (ZD6474) is a potent inhibitor of VEGFR2 with IC50 of 40 nM in a cell-free assay. It also inhibits VEGFR3 and EGFR with IC50 of 110 nM and 500 nM, respectively. Not sensitive to PDGFRβ, Flt1, Tie-2 and FGFR1 with IC50 of 1.1-3.6 μM. No activity against MEK, CDK2, c-Kit, erbB2, FAK, PDK1, Akt and IGF-1R with IC50 above 10 μM. Vandetanib (ZD6474) increases apoptosis and induces autophagy by increasing the level of reactive oxygen species (ROS).
||Vanillic acid (4-hydroxy-3-methoxybenzoic acid) is a flavoring agent which is also an intermediate in the production of vanillin from ferulic acid. Vanillic acid inhibits NF-κB activation. Anti-inflammatory, antibacterial, and chemopreventive effects.
||Vanillin (FEMA 3107), 4-hydroxy-3-methoxybenzaldehyde, is a food additive.
||Vanillyl alcohol (4-Hydroxy-3-methoxybenzyl alcohol, Vanillin alcohol, Vanillic alcohol, 3-Methoxy-4-hydroxybenzyl alcohol), derived from vanillin, is used to flavor food.
||Vanillyl Butyl Ether
||Vanillyl Butyl Ether (4-(Butoxymethyl)-2-methoxyphenol), an ether of monohydroxybenzoic acid, is added to food products as a flavoring agent. It is also present in cosmetics and personal care products as a fragrance ingredient, oral care agent, hair conditioning agent, and warming or cooling agent.
||Vanillylacetone (NSC 15335) is similar in chemical structure to other flavor chemicals such as vanillin and eugenol and is used as a flavor additive in spice oils and in perfumery to introduce spicy aromas. Vanillylacetone (Zingerone) alleviates oxidative stress and inflammation, down-regulates NF-κB mediated signaling pathways. Zingerone acts as an anti-mitotic agent, and inhibits the growth of neuroblastoma cells.
||Vanillylmandelic acid (VMA) is a chemical intermediate in the synthesis of artificial vanilla flavorings and is an end-stage metabolite of the catecholamines
||Vanin-1-IN-1 (VUN34002) is an inhibitor of vanin-1 enzyme which is a cell surface associated, giycosyiphosphatidyS inositol (GPi) anchored protein and plays an important role in metabolism and inflammation.
||Vanoxerine (GBR-12909) is a potent and selective inhibitor of the presynaptic dopamine uptake complex.
||Vardenafil HCl Trihydrate
||Vardenafil HCl Trihydrate (BAY38-9456) is a new type PDE inhibitor with IC50 of 0.7 and 180 nM for PDE5 and PDE1, respectively.
||Vardenafil (BAY38-9456, Levitra, Staxyn) hydrochloride is a selective, orally active, potent inhibitor of phosphodiesterase (PDE) with IC50 of 0.7 nM, 11 nM and 180 nM for PDE5, PDE6 and PDE1, respectively.
||Varenicline is highly selective and blocks more potently to α4β2 receptors than to other common nicotinic receptors (>500-fold α3β4, >3,500-fold α7, >20,000-fold α1βγδ), or to non-nicotinic receptors and transporters (>2,000-fold). Varenicline also acts as an agonist of 5-HT3 serotonine receptors.
||Varenicline (CP 526555) dihydrochloride
||Varenicline (CP 526555, Chantix, Champix) dihydrochloride is a potent, partial agonist of α4β2 nicotinic acetylcholine receptor (nAChR) and α3β4 nAChR with EC50 of 2.3 μM and 55 μM, respectively. Varenicline dihydrochloride is a potent, full agonist of α7 nAChRs with EC50 of 18 μM. Varenicline is a prescription medication used for smoking cessation.
||Varenicline (CP 526555) Hydrochloride is a potent and selective inhibitor of nicotine acetylcholine receptor (nAChR) with Ki of 0.12 nM and 0.14 nM for α6β2 nAChR and α4β2 nAChR, respectively.
||Varenicline Tartrate (CP 526555-18)
||Varenicline Tartrate (CP 526555-18, Chantix, Champix) is a nicotinic AChR partial agonist, used to treat nicotine addiction.
||Varespladib (LY315920) is a potent and selective human non-pancreatic secretory phospholipase A2 (hnsPLA) inhibitor with IC50 of 7 nM. Phase 3.
||Varlitinib (ARRY334543) is a selective and potent ErbB1(EGFR) and ErbB2(HER2) inhibitor with IC50 of 7 nM and 2 nM, respectively. Phase 2.
||VAS2870 is a pan-NADPH oxidase (NOX) inhibitor.
||Vasicine, an alkaloid isolated from A. vasica, is a potential natural cholinesterase inhibitor, exhibits promising anticholinesterase activity in preclinical models and has been in development for treatment of Alzheimer’s disease.
||VASP Rabbit Recombinant mAb
||VASP Rabbit Recombinant mAb detects endogenous level of toal VASP.
||Vatalanib (PTK787) 2HCl
||Vatalanib 2HCl (PTK787, ZK 222584, cpg-79787) is an inhibitor of VEGFR2/KDR with IC50 of 37 nM in a cell-free assay, less potent against VEGFR1/Flt-1, 18-fold against VEGFR3/Flt-4. Phase 3.
||VAV2 Rabbit Recombinant mAb
||VAV2 Rabbit Recombinant mAb detects endogenous level of total VAV2.
||VBIT-4 is a voltage-dependent anion channel (VDAC) oligomerization inhibitor that decreases mitochondrial DNA (mtDNA) release, type I interferon (IFN) signaling, neutrophil extracellular traps, and disease severity in a mouse model of systemic lupus erythematosus.
||Vc-MMAD (VCMMAD) is a drug-linker conjugate for antibody-drug-conjugation (ADC). Vc-MMAD is consisted of the ADCs linker (Val-Cit) and the potent tubulin inhibitor (MMAD).
||VcMMAE (mc-vc-PAB-MMAE), a MMAE derivative with valine-citrulline (Vc) linker,is an antibody-drug conjugate (ADC) with potent antitumor activity. MMAE is a synthetic antineoplastic agent and can be efficiently released from VcMMAE in vitro and exert cytotoxic activity.
||VDAC1 Rabbit Recombinant mAb
||VDAC1 Rabbit Recombinant mAb detects endogenous level of total VDAC1.
||Vecuronium Bromide (ORG NC45) is a non-depolarizing neuromuscular blocking agent, used for skeletal muscle relaxation during surgery.
||Veliparib (ABT-888, NSC 737664) is a potent inhibitor of PARP1 and PARP2 with Ki of 5.2 nM and 2.9 nM in cell-free assays, respectively. It is inactive to SIRT2. Veliparib increases autophagy and apoptosis. Phase 3.
||Velpatasvir (GS-5816) is a second-generation NS5A inhibitor that inhibits hepatitis C viral replication through acting on the crucial "membranous web" that facilitates RNA replication.
||Vemurafenib (PLX4032, RG7204, RO5185426) is a novel and potent inhibitor of B-RafV600E with IC50 of 31 nM in cell-free assay. 10-fold selective for B-RafV600E over wild-type B-Raf in enzymatic assays and the cellular selectivity can exceed 100-fold. Vemurafenib (PLX4032, RG7204) induces autophagy.
||Venetoclax (ABT-199, GDC-0199) is a Bcl-2-selective inhibitor with Ki of <0.01 nM in cell-free assays, >4800-fold more selective versus Bcl-xL and Bcl-w, and no activity to Mcl-1. Venetoclax is reported to induce cell growth suppression, apoptosis, cell cycle arrest, and autophagy in triple negative breast cancer MDA-MB-231 cells. Phase 3.
||Venlafaxine (Wy 45030) is an arylalkanolamine serotonin-norepinephrine reuptake inhibitor (SNRI), used to treat major depressive disorder (MDD), generalised anxiety disorder (GAD), panic disorder and social phobia.
||Venlafaxine HCl is an arylalkanolamine serotonin-norepinephrine reuptake inhibitor (SNRI), used to treat major depressive disorder (MDD), generalised anxiety disorder (GAD), panic disorder and social phobia.
||VER-49009 (CCT0129397) is a potent HSP90 inhibitor with IC50 of 47 nM for HSP90β.
||VER155008 (C07) is a potent Hsp70 family inhibitor with IC50 of 0.5 μM, 2.6 μM, and 2.6 μM in cell-free assays for HSP70, HSC70, and GRP78 (HSPA5, Bip), respectively, >100-fold selectivity over HSP90. VER155008 inhibits autophagy and causes reduced levels of HSP90 client proteins.
||Verapamil (CP-16533-1) HCl
||Verapamil HCl (CP-16533-1) is an L-type calcium channel blocker that is a class IV anti-arrhythmia agent. Verapamil inhibits both permeability-glycoprotein (P-gp) and CYP3A4.
||Veratraldehyde (3,4-dimethoxybenzaldehyde, VD, VAD, VAld, Verapamil Related Compound E, Methylvanillin), a derivative of vanillin, is the chemical that is found and isolated from peppermint, ginger, bourbon vanilla, and fruits such as raspberry. Veratraldehyde is widely used as a flavorant and odorant because of its pleasant woody fragrance. Veratraldehyde also acts as a redox cycle agent.
||Veratramine (NSC 17821, NSC 23880), a major alkaloid from Veratrum nigrum L., has distinct anti-tumor and anti-hypertension effects. It is a good membrane permeant, undergoes rapid passive diffusion, and has a good stability in the gastrointestinal tract during its absorption.
||Veratric acid (3,4-Dimethoxybenzoic acid), a simple benzoic acid derived from plants and fruits, has anti-oxidant, anti-inflammation, and blood pressure-lowering effects. Veratric acid reduces upregulated COX-2 expression, and levels of PGE2, IL-6 after UVB irradiation.
||Veratridine (Cevadine, Cevadin, Cevadene), a steroidal alkaloid found in plants of the lily family, is a voltage-gated sodium channel activator. Veratridine induces anxiogenic-like behaviors in rats.
||Veratryl alcohol (VA, Veratrole alcohol, 3,4-Dimethoxybenzyl alcohol), a secondary metabolite of some lignin degrading fungi, is the natural substrate of Lignin peroxidase (LiP).
||Verbascoside (Acteoside, Kusaginin), a phenylpropanoid glycoside from lemon verbena, has several biological properties such as anti-inflammatory, antimicrobial, antitumor, and antioxidant.
||Verbenalin (Verbenalol β-D-glucopyranoside, Verbenalol glucoside, Cornin), an iridoid glycoside found in Verbena officinalis, has been reported to exhibit uterine stimulant activity and demonstrated cardioprotection against experimental myocardial ischemic injury.
Vercirnon (GSK-1605786, CCX282-B, Traficet-EN) is selective and potent antagonist of CCR9. Vercirnon inhibits CCR9-mediated Ca2+ mobilization and chemotaxis on Molt-4 cells with IC50 values of 5.4 and 3.4 nM, respectively.
||Verdinexor (KPT-335, ATG-527) is an orally bioavailable, selective XPO1/CRM1 inhibitor.
||Verdiperstat (AZD3241, BHV-3241) is a selective, orally active and irreversible inhibitor of myeloperoxidase (MPO) with IC50 of 630 nM. Verdiperstat (AZD3241) can be used in the research of neurodegenerative brain disorders.
||Vericiguat (BAY1021189, Verquvo) is a potent, orally available and soluble guanylate cyclase (sGC) stimulator.
||Verinurad (RDEA3170) is a high-affinity inhibitor of the URAT1 transporter with an IC50 of 25 nM for inhibiting transport activity of human URAT1. It inhibits the related URAT1 homologs OAT4 and OAT1 with approximately 200-fold lower affinity compared to URAT1 with IC50 values of 5.9 µM and 4.6 µM, respectively.
||Vernakalant (RSD1235) Hydrochloride
Vernakalant (RSD-1235, MK-6621) is a novel, frequency-dependent Na+ channel and early activating K+ channel blocker that selectively prolongs the atrial refractory period.
||Verteporfin (CL 318952)
||Verteporfin (CL 318952, Visudyne) is a small molecule that inhibits TEAD–YAP association and YAP-induced liver overgrowth. It is also a potent second-generation photosensitizing agent derived from porphyrin. Verteporfin is an autophagy inhibitor. Verteporfin inhibits cell proliferation and induces apoptosis.
||Verubecestat (MK-8931) is a potent and selective beta-secretase (also known as Beta-site APP-cleaving enzyme 1) inhibitor.
||Verubecestat (MK-8931) Trifluoroacetate
||Verubecestat (MK-8931) Trifluoroacetate is a potent and selective beta-secretase inhibitor and BACE1 protein inhibitor or Beta-site APP-cleaving enzyme 1 inhibitor.
Verubulin (MPC-6827), a microtubule-disrupting agent with potent and broad-spectrum cytotoxic activities, acts as a promising candidate for the treatment of multiple cancer types.
||Vesatolimod (GS-9620) is a potent and selective orally active small molecule agonist of Toll-like receptor 7.
||VGX-1027 (GIT 27) is an orally active immunomodulator. Phase 1.
||VH298 is a potent VHL (Von Hippel-Lindau, the E3 ligase) inhibitor that stabilizes HIF-α. VH298 blocks the VHL:HIF-α interaction with Kd of 90 nM in isothermal titration calorimetry (ITC) and 80 nM in a competitive fluorescence polarization assay. VH-298 can be used in PROTAC technology.
||Vibostolimab (anti-TIGIT, MK-7684) is a humanized monoclonal antibody that binds to the T-cell immunoreceptor with immunoglobulin and ITIM domains (TIGIT), blocking the interaction between TIGIT and its ligands, CD112 and CD155, thereby activating T lymphocytes which help to destroy tumor cells.
||Vicriviroc is a potent CCR5 antagonist with IC50 of 0.91 nM, showing broad-spectrum activity against genetically diverse HIV-1 isolates, and also drug-resistant viruses with RTI, PRI, or MDR phenotypes. Phase 3.
||Vicriviroc (SCH-417690, SCH-D) maleate is a potent, selective, oral bioavailable and CNS penetrated antagonist of CCR5 with Ki of 2.5 nM. Vicriviroc also inhibits HIV-1 in PBMC cells, with IC90 of 3.3 nM (JrFL), 2.8 nM (ADA-M), 1.8 nM (301657), 4.9 nM (JV1083) and 10 nM (RU 570), respectively.
||Vidarabine is an antiviral drug by interfering with the synthesis of viral DNA, used to treat herpes simplex and varicella zoster viruses.
||Vidarabine (Spongoadenosine, Vira-A) is a nucleoside antibiotic with antiviral acitivity that interferes with the synthesis of viral DNA. It is used to treat herpes simplex and varicella zoster viruses.
||Vidofludimus (SC12267, 4SC-101) is an orally active and potent dihydroorotate dehydrogenase (DHODH) inhibitor with IC50 of 134 nM for human DHODH. Vidofludimus calcium (IMU-838) is investigated as a potential treatment option for COVID-19. Phase 2.
||Vilanterol trifenatate (GW642444M) is a novel inhaled long-acting beta2 adrenoceptor agonist with inherent 24-hour activity for once daily treatment of COPD and asthma.
||Vilazodone (EMD-68843, SB-659746A) is a novel antidepressant having a selective serotonin (5-HT) reuptake inhibitory and 5-HT1A receptor partial agonist activity. The affinity of vilazodone is much higher in the 5-HT reuptake site (Ki=0.1 nM) than in norepinephrine (Ki=56 nM) and dopamine (Ki=37 nM) sites.
||Vilazodone HCl is a selective serotonin reuptake inhibitor (SSRI) and a partial agonist of 5-HT1A receptors, used for the treatment of major depressive disorder.
||Vildagliptin (LAF-237) inhibits DPP−4 with IC50 of 2.3 nM.
||Vinblastine (NSC-49842) sulfate
||Vinblastine sulfate (NSC49842, Vincaleukoblastine sulfate salt, 29060-LE, Exal, Velban, Velbe) inhibits microtubule formation and suppresses nAChR activity with IC50 of 8.9 μM in a cell-free assay, used to treat certain kinds of cancer. Vinblastine sulfate induces autophagy and apoptosis.
||Vinburnine ((-)-Eburnamonine, Vincamone, L-Eburnamonine) is a vasodilator. It is a vinca alkaloid and a metabolite of vincamine.
||Vincamine (Angiopac, Devincan, Equipur, Minorin, Novicet, Oxybral, Perval, Sostenil, Tripervan), an indole alkaloid found in the leaves of V. minor and C. roseus, is a peripheral vasodilator that increases blood flow to the brain.
||Vincristine (Leurocristine, NSC-67574, 22-Oxovincaleukoblastine) is a natural alkaloid isolated from the plant Vinca rosea Linn. with anti-tumor activity. Vincristine inhibits microtubule formation in mitotic spindle and binds to microtubule with Ki of 85 nM.
||Vincristine (NSC-67574) sulfate
||Vincristine sulfate (NSC-67574, Leurocristine, Oncovin, 22-Oxovincaleukoblastine) is an inhibitor of polymerization of microtubules by binding to tubulin with IC50 of 32 μM in a cell-free assay. Vincristine sulfate induces apoptosis.
||Vindesine sulfate (Eldesine, Eldisine, Desacetyl Vinblastine amide, Desacetylvinblastine amide, DAVA, DVA, VDS), a vinca alkaloid derived from Catharanthus roseus, is a potent inhibitor of mitosis with antineoplastic activities. Vindesine binds to the microtubular proteins of the mitotic spindle, leading to crystallization of the microtubule and mitotic arrest or cell death.
||Vindoline is a chemical precursor to vinblastine and exhibits antimitotic activity by inhibiting microtubule assembly.
||Vinorelbine ditartrate (KW-2307)
||Vinorelbine Tartrate (KW-2307, Nor-5'-anhydrovinblastine ditartrate) is a semi-synthetic vinca alkaloid, and inhibits mitosis through interaction with tubulin. Vinorelbine Tartrate exhibits anti-tumor activities via inducing the mitotic apoptosis, autophagy and inflammation.
||Vinpocetine (RGH-4405) is a selective inhibitor of voltage-sensitive sodium channel for the treatment of stroke, vascular dementia and Alzheimer's disease.
||Vipivotide tetraxetan (PSMA-617)
||Vipivotide tetraxetan (PSMA-617) is a chemically modified PSMA(prostate-specific membrane antigen) inhibitor with a Ki of 0.37 nM.
||Vismodegib (GDC-0449) is a potent, novel and specific hedgehog inhibitor with IC50 of 3 nM and also inhibits P-gp with IC50 of 3.0 μM in a cell-free assay.
||Visomitin (SKQ1) is a novel mitochondrial-targeted antioxidant that holds promise in the treatment of inflammation associated with ocular surface diseases such as dry eye disease (DED) and corneal wounds. SkQ1 shows a TC50 of 317 nM on HCjE cells.
||Vistusertib (AZD2014) is a novel mTOR inhibitor with IC50 of 2.8 nM in a cell-free assay; highly selective against multiple PI3K isoforms (α/β/γ/δ). AZD2014 showed no or weak binding to the majority of kinases when tested at 1 μM. AZD2014 induces proliferation suppression, apoptosis, cell cycle arrest, and autophagy in HCC cells with antitumor activity.
||Vitamin A (Retinol) is a naturally occuring fat-soluble vitamin that is important for normal vision, the immune system, and reproduction. It also plays roles in normal functioning of heart, lungs, kidneys, and other organs.
||Vitamin A Acetate
||Vitamin A Acetate (Retinyl, Retinol) is a group of unsaturated nutritional hydrocarbons, that includes retinol, retinal, retinoic acid, and several provitamin A carotenoids, among which beta-carotene is the most important.
||Vitamin B12 (Cobalamin, Cyanocobalamin) is a water soluble vitamin with a key role in the normal functioning of the brain and nervous system, and for the formation of blood.
||Vitamin C (Ascorbic acid) is a water-soluble vitamin indicated for the prevention and treatment of scurvy.
||Vitamin D2 (Ergocalciferol) is a selective inhibitor of mammalian DNA polymerase A (pol A) with IC50 of 123 μM.
||Vitamin E (D-alpha-Tocopherol) is a fat-soluble vitamin with potent antioxidant properties. It is a potent peroxyl radical scavenger and inhibits noncompetitively cyclooxygenase activity in many tissues, also inhibits angiogenesis and tumor dormancy through suppressing vascular endothelial growth factor (VEGF) gene transcription.
||Vitamin E Acetate
||Vitamin E Acetate (Tocopherol) is the stable form of Vitamin E most often used in cosmetic formulations for its skin care benefits. It protects the cells against free radicals and prevents the peroxidation of body fats as an in-vivo antioxidant.
||Vitamin K1 (Phyllohydroquinone, Phylloquinone, Phytomenadione, Phytonadione), made by plants, is a major type of dietary vitamin K, which is well-known for its role in blood clotting. Vitamin K1 is directly involved in photosynthesis.
||Vitamin K2 (Menaquinone) is an important fat-soluble vitamin that plays critical roles in protecting heart and brain, and building strong bones. It also plays an important role in cancer protection.
||Vitamin U (Methylmethioninesulfonium Chloride, Cabagin-U, Smethylmethionine) is a vitamin found in green vegetables. It is used in the treatment of peptic ulcers, colitis, and gastritis and has an effect on secretory, acid-forming, and enzymatic functions of the intestinal tract.
||Vitexin (Apigenin-8-C-glucoside), an naturally occuring apigenin flavone glycoside, acts as a platelet aggregation and alpha-glucosidase inhibitor and shows antineoplastic activity.
||Vitexin-2-O-rhamnoside (2''-O-Rhamnosylvitexin, Apigenin-8-C-glucoside) is one of the main components of flavonoid of the leaves of Crataegus pinnatifida Bge. var major N. E. Br. It has many biological and pharmacological activities, such as antioxidation and treating heart disease.
||VK-II-36 is a carvedilol analog that suppresses sarcoplasmic reticulum (SR) Ca(2+) release but does not block the β-receptor.
||VL285 is a potent VHL ligand that degrades HaloTag7 fusion proteins. Cotreatment with excess VL285, the core VHL ligand from which HaloPROTAC3 is derived, is able to significantly reduce HaloPROTAC3 mediated activity to 50% degradation.
||VLX1570 is a competitive inhibitor of proteasome DUB activity, with an IC50 of ~10 μM in vitro.
||VLX600 is a novel iron-chelating inhibitor of oxidative phosphorylation (OXPHOS), potentiates the effect of radiation in tumor spheroids in a synergistic manner. VLX600 shows enhanced cytotoxic activity under conditions of nutrient starvation. VLX600 induces autophagy and mitochondrial inhibition with antitumor activity.
||VO-Ohpic is a potent inhibitor of PTEN (phosphatase and tensin homolog) with IC50 of 35 nM.
||Vodobatinib (K0706, SCO-088, SUN K706, SUN-K0706) is a novel BCR-ABL1 tyrosine kinase inhibitor with an IC50 of 7 nM. Vodobatinib exhibits activity against most BCR-ABL1 point mutants with IC50s of 167 nM, 154 nM,165 nM and 1967 nM for BCR-ABL1L248R, BCR-ABL1Y253H , BCR-ABL1E255V and BCR-ABL1T315I, respectively.
||Voglibose (AO 128) is an N-substituted derivative of valiolamine, excellent inhibitory activity against α-glucosidases and its action against hyperglycemia and various disorders caused by hyperglycemia.
||Volasertib (BI 6727)
||Volasertib (BI 6727) is a highly potent Plk1 inhibitor with IC50 of 0.87 nM in a cell-free assay. It shows 6- and 65-fold greater selectivity against Plk2 and Plk3. Volasertib induces cell cycle arrest and apoptosis in various cancer cells. Phase 3.
||Volinanserin (Volinanserin Hydrochloride Salt, MDL100907, M 100907, MDL-100,907) is a highly selective and potent 5-HT2 receptor antagonist with Ki of 0.36 nM. Volinanserin shows antipsychotic activity.
||Vonafexor (EYP001, PLX007) is a novel non-bile acid, selective, second generation farnesoid X receptor (FXR) agonist.
||Vonoprazan Fumarate (TAK-438)
||Vonoprazan Fumarate (TAK-438) is a novel P-CAB (potassium-competitive acid blocker) that reversibly inhibits H+/K+, ATPase with IC50 of 19 nM (pH 6.5), controls gastric acid secretion. Phase 3.
||Vorapaxar (SCH 530348, MK-5348) is a potent and orally active thrombin receptor (PAR-1) antagonist with Ki of 8.1 nM.
||Vorasidenib (AG-881) is an orally available inhibitor of mutated forms of both isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2).
||Voreloxin (SNS-595) hydrochloride
||Voreloxin hydrochloride (SNS-595, Vosaroxin) is a potent Topoisomerase II inhibitor with broad-spectrum anti-tumor activity. Phase 2.
||Voriconazole (UK-109496) is a new triazole derivative similar to fluconazole and itraconazole that acts by inhibiting fungal cytochrome P-450-dependent, 14-alpha-sterol demethylase-mediated synthesis of ergosterol.
||Vorinostat (suberoylanilide hydroxamic acid, SAHA, MK0683, Zolinza) is an HDAC inhibitor with IC50 of ~10 nM in a cell-free assay. Vorinostat abrogates productive HPV-18 DNA amplification.
||Vortioxetine, a novel antidepressant for the treatment of major depressive disorder, is a 5-HT3, 5-HT7 and 5-HT1D receptor antagonist, 5-HT1B receptor partial agonist, 5-HT1A receptor agonist and serotonin (5-HT) transporter (SERT) inhibitor.
||Vortioxetine (Lu AA21004) HBr
||Vortioxetine (Lu AA21004), a multimodal serotonergic agent, is an antagonist of human (h) serotonin (5-HT)3A receptor and h5-HT7 receptor with Ki of 3.7 nM and 19 nM, respectively. Vortioxetine (Lu AA21004) is also a h5-HT1B receptor partial agonist with Ki of 33 nM and h5-HT1A receptor agonist with Ki of 15 nM, and a human 5-HT transporter (SERT) inhibitor with Ki of 1.6 nM.
||Voxelotor (GBT440, GTx011) is a novel small molecule hemoglobin modifier which increases hemoglobin oxygen affinity.
||Voxtalisib (SAR245409, XL765) is a dual inhibitor of mTOR/PI3K, mostly for p110γ with IC50 of 9 nM; also inhibits DNA-PK and mTOR. Phase 1/2.
||Voxtalisib (XL765) Analogue
||Voxtalisib (SAR245409, XL765) Analogue is a dual inhibitor of mTOR/PI3K, mostly for p110γ with IC50 of 9 nM; also inhibits DNA-PK and mTOR. Phase 1/2.
||VP3.15 dihydrobromide is a potent, orally bioavailable and CNS-penetrant dual inhibitor of phosphodiesterase (PDE)7 and glycogen synthase kinase (GSK)3 with IC50 of 1.59 μM and 0.88 μM for PDE7 and GSK-3, respectively. VP3.15 dihydrobromide has neuroprotective and neuroreparative activities and can be used as potential combined anti-inflammatory and pro-remyelinating therapies for multiple sclerosis (MS).
||VPC-80051 is an potent inhibitor of hnRNP A1 splicing activity that targets hnRNP A1 RBD and reduces AR-V7 messenger levels in 22Rv1 CRPC cell line.
||VPS34 inhibitor 1 (Compound 19)
||VPS34 inhibitor 1 (Compound 19, PIK-III analogue) is a potent and selective inhibitor of VPS34 with an IC50 of 15 nM.
||Vps34-IN1 is a potent and highly selective Vps34 inhibitor with IC50 of 25 nM invitro,which does not significantly inhibit the isoforms of class I as well as class II PI3Ks. Vps34-IN1 modulates autophagy.
||VR23 is a potent proteasome inhibitor with IC50 of 1 nM, 50-100 nM, and 3 μM for trypsin-like proteasomes, chymotrypsin-like proteasomes, and caspase-like proteasomes, respectively.
||VS-5584 (SB2343) is a potent and selective dual PI3K/mTOR inhibitor for mTOR, PI3Kα/β/δ/γ with IC50 of 3.4 nM and 2.6-21 nM, respectively. Phase 1.
||VTP-27999 TFA (VTP-27999 Trifluoroacetate, VTP-27999 2,2,2-trifluoroacetate) is an orally efficacious, selecitive alkyl amine renin inhibitor with IC50 of 0.47 nM for 0.3 nM of purified recombinant human renin.
||VTP50469 is a potent, highly selective and orally active inhibitor of Menin-MLL interaction with Ki of 104 pM. VTP50469 exhibits anti-leukemia activity.
||VTX-27 (Compound 27) is a potent and selective inhibitor of protein kinase C θ (PKC θ) with Ki of 0.08 nM and 16 nM for PKC θ and PKC δ, respectively.
VU-1545 is a metabotropic glutamate receptor 5 positive allosteric modulator (mGluR5 PAM) with a Ki of 156 nM and an EC50 of 9.6 nM.
||VU-29 is a selective, positive allosteric modulator (PAM) of metabotropic glutamate 5 (mGlu5) receptor with EC50 of 9 nM and Ki of 244 nM for rmGluR5. VU-29 is selective for mGluR5 relative to other mGluR subtypes with EC50 of 557 nM, 1.5 μM and 154 nM for rmGluR1, rmGluR2 and hmGluR4.
||VU0071063 is a Kir6.2/SUR1 activator.
||VU0119498 is a pan Gq muscarinic acetylcholine receptor (mAChR) M1, M3, M5 positive allosteric modulator (PAM) with EC50 of 6.1 μM, 6.4 μM, 4.1 μM, respectively.
||VU0134992 is a selective inward rectifier potassium (Kir) channel Kir4.1 blocker with IC50 of 0.97 µM.
||VU0134992 hydrochloride is a subtype-preferring, orally active and selective Kir4.1 potassium channel pore blocker with IC50 of 0.97 µM.
VU0152100 is a potent and selective allosteric potentiator of M4 mAChR with an EC50 of 380 nM.
VU0152100 (VU152100) is a potent and selective allosteric potentiator of M4 mAChR with an EC50 of 380 nM.
||VU0238429 (M5 PAM) is the first positive allosteric modulator of muscarinic acetylcholine receptor subtype 5 (mAChR5/M5) with EC50 of 1.16 μM at M5 and both > 30 μM at M1 and M3. VU0238429 shows no potentiator activity at M2 or M4.
||VU0238441 is a pan muscarinic acetylcholine receptor (mAChR) positive allosteric modulator (PAM) with EC50 of 2.1 μM, 2.2 μM, 2.8 μM, 3.2 μM and >10 μM for M5, M3, M2, M1 and M4, respectively.
||VU0357017 hydrochloride (CID-25010775) is a potent, highly selective and CNS-penetrant agonist of M1 which is a subtype of muscarinic acetylcholine receptors (mAChRs). VU0357017 hydrochloride appears to act at an allosteric site to activate the receptor with EC50 of 477 nM and Ki of 9.91 μM.
||VU0810464 is a potent and selective activator of non-ureaG protein-gated inwardly-rectifying potassium channels (GIRK/Kir3). VU0810464 displays nanomolar potency for neuronal with EC50 of 165 nM and GIRK1/4 with EC50 of 720 nM channels with improved brain penetration.
VU10010 is a potent, highly selective and allosteric M4 mAChR potentiator with an EC50 of 400 nM.
||VU0453595 is a M1 positive allosteric modulator (PAM). VU0453595 is potential in schizophrenia.
||VU6015929 is a selective Discoidin Domain Receptor 1/2 (DDR1/2) inhibitor with IC50 of 4.67 nM and 7.39 nM for DDR1 and DDR2, respectively. VU6015929 potently inhibits collagen-IV production.
||VU661013 is a novel, potent, selective MCL1 inhibitor with Ki of 97 ± 30 pM of human MCL-1 in a TR-FRET assay. However, VU661013 does not significantly inhibit BCL-xL or BCL-2 with Ki > 40 μM or = 0.73 μM. VU661013 de-stabilizes BIM/MCL-1 association, leads to apoptosis in AML.
||VUF10460 is a histamine H4 receptor agonist.
||VUN65671 (Compound 35) is a potent entry inhibitor of Ebola and Marburg virus infections.
VUT-MK142 is a potent new cardiomyogenic synthetic agent that promotes the differentiation of pre-cardiac mesoderm into cardiomyocytes.
||VX-11e (VTX-11e, Vertex-11e) is a potent, selective, and orally bioavailable ERK2 inhibitor with Ki of <2 nM, over 200-fold selective over other kinases tested.
||VX-150 (EOS-62073) is an orally bioavailable pro-drug that rapidly converts into its active moiety, which is a highly selective inhibitor of NaV1.8 relative to the other sodium channel subtypes (>400-fold).
||VX-702 is a highly selective inhibitor of p38α MAPK, 14-fold higher potency against the p38α versus p38β. Phase 2.
||VX-803 (M4344, ATR inhibitor 2) is an ATP-competitive, orally active, and selective inhibitor of ataxia telangiectasia and Rad3 related (ATR) kinase with Ki of < 150 pM. VX-803 (M4344) potently inhibits ATR-driven phosphorylated checkpoint kinase-1 (P-Chk1) phosphorylation with IC50 of 8 nM. VX-803 (M4344) exhibits potential antineoplastic activity.
δ-Valerolactone (Tetrahydro-2H-pyran-2-one, 5-Valerolactone, oxan-2-one) is an endogenous metabolite.